Role of gene sequencing in classifying struma ovarii: BRAF p.G469A mutation and TERT promoter alterations favour malignant struma ovarii
Open Access
- 28 September 2023
- journal article
- research article
- Published by Wiley in Histopathology
- Vol. 84 (2) , 291-300
Abstract
Aims: Struma ovarii (SO) are rare, accounting for 0.3–1% of ovarian tumours, and include benign and malignant lesions. In most cases, histology is not predictive of clinical outcome and prognosis. The prognosis of histologically malignant thyroid‐type carcinomas can indeed be excellent, while SO, composed of normal thyroid tissue, can recur and are designated highly differentiated follicular carcinoma of the ovary. Clearer diagnostic criteria are therefore required.Methods and results: We retrospectively studied 31 SO using DNA and RNA sequencing with pan‐cancer gene panels, including eight biologically malignant SO (BMSO) defined based on ovarian serosal or extra‐ovarian dissemination at presentation or during follow‐up, 10 stage IA histologically malignant SO (HMSO) with thyroid‐type carcinoma morphology and 13 biologically and histologically benign SO (BSO), with none of the above‐mentioned characteristics. Molecular alterations were observed in 87.5% of BMSO, 70% of HMSO and 7.7% of BSO (P < 0.001). All patients with a peritoneal dissemination at presentation or during follow‐up had at least one gene alteration. BRAF mutations (44.5%) were only observed in malignant forms (HMSO and BMSO) and TERT promoter alterations (25%) only in cases of BMSO. The BRAF p.G469A mutation, which is extremely rare in thyroid carcinomas, was the molecular alteration most frequently associated with malignant SO (28.5%).Conclusion: Our results highlight the clinical utility of molecular sequencing in SO, based on this limited number of cases. However, as malignant SO evolve slowly, more extensive molecular studies in SO with more than 10 years’ follow‐up are required to draw any conclusions on the prognostic value of the associated gene alterations.Keywords
This publication has 37 references indexed in Scilit:
- Unilateral follicular variant of papillary thyroid carcinoma with unique KRAS mutation in struma ovarii in bilateral ovarian teratoma: a rare case reportBMC Cancer, 2012
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Expression of Benign and Malignant Thyroid Tissue in Ovarian Teratomas and the Importance of Multimodal Management as Illustrated by a BRAF -Positive Follicular Variant of Papillary Thyroid CancerThyroid®, 2010
- Natural History of Biologically Malignant Struma Ovarii: Analysis of 27 Cases With Extraovarian SpreadInternational Journal of Gynecological Pathology, 2010
- A follicular variant of papillary thyroid carcinoma in struma ovarii. Case report with unique molecular alterationsHistopathology, 2009
- Malignant Struma Ovarii: An Analysis of 88 Cases, Including 27 With Extraovarian SpreadInternational Journal of Gynecological Pathology, 2009
- Typical Thyroid-Type Carcinoma Arising in Struma Ovarii: A Report of 4 Cases and Review of the LiteratureInternational Journal of Gynecological Pathology, 2008
- BRAF T1799A Mutation Occurring in a Case of Malignant Struma OvariiInternational Journal of Surgical Pathology, 2007
- RET/PTC3 Rearrangement and Thyroid Differentiation Gene Analysis in a Struma Ovarii Fortuitously Revealed by Elevated Serum Thyroglobulin ConcentrationThyroid®, 2005
- Proliferative and Histologically Malignant Struma OvariiInternational Journal of Gynecological Pathology, 1993